{
  "docId": "019de075-f745-744d-a2c3-62fcecd316e9",
  "docSlug": "352ee416e6a97a9b39e1309fafdab0f3",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 38,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide highlights a combination therapy approach involving oncolytic immunotherapy and adoptive cell therapy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/23",
  "deckHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9",
  "deckJsonHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json",
  "deckAnchorHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.28,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "list",
      "text": "V2ACT Immunotherapy, combines an oncolytic immunotherapy and adoptive cell therapy. Induces an acute inflammatory response in the tumor and converts tumor microenvironment from immunosuppressive to immunostimulatory; Anticipated to enhance effect of neoantigen specific effector T cells",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a229b67e-1349-4988-85d8-b31da355231d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.62,
        "x": 0.35,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "V2ACT Therapeutics is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. established to develop and test V2ACT. Vaccination increases the numbers of neoantigen-specific T cells in the body and Olvi-Vec kills cancer cells and potentiates T cells by increasing cancer tissue receptivity to adoptively transferred neoantigen-specific effector T cells.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fb9259e-d410-4d0a-85ff-0c2e186a9a26",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.62,
        "x": 0.35,
        "y": 0.74
      },
      "kind": "source-note",
      "text": "Novel IO modality: United States Patent No. 11,633,442, issued in April 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a5fa367-00f6-4716-88f2-2535cd0da056",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.62,
        "x": 0.35,
        "y": 0.45
      },
      "kind": "table",
      "text": "Technology | TVI Adoptive Cell Therapy | Olvi-Vec Oncolytic Immunotherapy; Patients Dosed | ~ 130 | ~ 150; Regulatory | Fast Track Designation / FDA Grant - glioblastoma | Phase 3 enrolling - ovarian",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4afa11d-01b0-4388-ae2d-98ce7a3581c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "V2ACT Therapeutics LLC: Joint Venture between GNLX and TVAX BioMedical",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1084ed66-fe6b-4c7f-b15e-72045530677a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 38,
      "from": 10,
      "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}